Technical Analysis for RCUS - Arcus Biosciences, Inc.

Grade Last Price % Change Price Change
C 34.7 2.21% 0.75
RCUS closed up 2.21 percent on Thursday, April 22, 2021, on 82 percent of normal volume. It was able to find support at its 50 day moving average.
Earnings due: May 3
*** please verify all earnings dates ***

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Up Up Up
Historical RCUS trend table...

Date Alert Name Type % Chg
50 DMA Support Bullish 0.00%
MACD Bullish Centerline Cross Bullish 0.00%
20 DMA Support Bullish 2.21%
Crossed Above 50 DMA Bullish 2.21%
20 DMA Support Bullish 8.61%
Spinning Top Other 8.61%
NR7 Range Contraction 8.61%
Down 3 Days in a Row Weakness 8.61%
Overbought Stochastic Strength 8.23%
Fell Below 50 DMA Bearish 4.74%
Older End-of-Day Signals for RCUS ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Up 2% about 7 hours ago
10 DMA Support about 7 hours ago
Up 1% about 7 hours ago
Rose Above Previous Day's High about 8 hours ago
50 DMA Support about 8 hours ago
View Earlier Intraday Alerts

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Arcus Biosciences, Inc. Description

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing cancer immunotherapies in the United States. The company develops various programs targeting immuno-oncology pathways, including AB928, a dual adenosine receptor antagonist, which is in a Phase I/Ib clinical trial; and AB122, an anti-PD-1 antibody that is in Phase I clinical trial. It is also developing AB154, an anti-T-cell immunoreceptor with Ig and ITIM domains antibody, which is in Phase I trial as monotherapy; and AB680, a small-molecule inhibitor of CD73 that is in Phase I healthy volunteer study. The company has a clinical development collaboration agreement with Strata Oncology, Inc. to evaluate AB122, an anti-PD-1 antibody. Arcus Biosciences, Inc. was founded in 2015 and is headquartered in Hayward, California.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Cancer Clinical Medicine Clinical Development Monoclonal Antibodies Cancer Treatments Cancer Immunotherapy Immunotherapies Adenosine Cd73 Pd 1

Is RCUS a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 42.2
52 Week Low 16.69
Average Volume 500,773
200-Day Moving Average 27.44
50-Day Moving Average 33.57
20-Day Moving Average 31.70
10-Day Moving Average 32.82
Average True Range 2.18
ADX 12.14
+DI 28.56
-DI 20.53
Chandelier Exit (Long, 3 ATRs ) 28.95
Chandelier Exit (Short, 3 ATRs ) 33.24
Upper Bollinger Band 35.71
Lower Bollinger Band 27.68
Percent B (%b) 0.87
BandWidth 25.33
MACD Line 0.02
MACD Signal Line -0.42
MACD Histogram 0.4347
Fundamentals Value
Market Cap 2.25 Billion
Num Shares 64.9 Million
EPS -1.59
Price-to-Earnings (P/E) Ratio -21.84
Price-to-Sales 15.64
Price-to-Book 2.91
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 37.91
Resistance 3 (R3) 37.64 36.29 37.38
Resistance 2 (R2) 36.29 35.48 36.43 37.20
Resistance 1 (R1) 35.50 34.97 35.90 35.77 37.02
Pivot Point 34.15 34.15 34.35 34.29 34.15
Support 1 (S1) 33.36 33.34 33.76 33.63 32.38
Support 2 (S2) 32.01 32.83 32.15 32.20
Support 3 (S3) 31.22 32.01 32.03
Support 4 (S4) 31.49